{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:22:17Z","timestamp":1792059737903,"version":"4.4.0"},"reference-count":33,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to estimate the cost-effectiveness of injectable extended-release naltrexone (XR-NTX) compared with methadone maintenance and buprenorphine maintenance treatment (MMT and BMT, respectively) for adult males enrolled in treatment for opioid dependence in the United States from the perspective of state-level addiction treatment payers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model with daily time cycles was used to estimate the incremental cost per opioid-free day in a simulated cohort of adult males aged 18\u201365 over a 6-month period from the state health program perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>XR-NTX is predicted to be more effective and more costly than methadone or buprenorphine in our target population, with an incremental cost per opioid-free day gained relative to the next-most effective treatment (MMT) of $72. The cost-effectiveness of XR-NTX relative to MMT was driven by its effectiveness in deterring opioid use while receiving treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>XR-NTX is a cost-effective medication for treating opioid dependence if state addiction treatment payers are willing to pay at least $72 per opioid-free day.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1080\/08897077.2015.1010031","type":"journal-article","created":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T17:57:03Z","timestamp":1426528623000},"page":"226-231","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":31,"title":["Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared with Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence"],"prefix":"10.1177","volume":"36","author":[{"given":"Heide","family":"Jackson","sequence":"first","affiliation":[{"name":"Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Mandell","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjana","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Vanness","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,4,1]]},"reference":[{"key":"bibr1-08897077.2015.1010031","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014."},{"key":"bibr2-08897077.2015.1010031","unstructured":"National Center for Injury Prevention and Control, CDC. Web-based Injury Statistics Query and Reporting System (WISQARS). 2014. Available at: http:\/\/www.cdc.gov\/injury\/wisqars\/fatal.html. Published 2014. Accessed November 5, 2014."},{"key":"bibr3-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2011.01075.x"},{"key":"bibr4-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00162-9"},{"key":"bibr5-08897077.2015.1010031","first-page":"1","author":"Lynch FL","year":"2014","journal-title":"Addict Sci Clin Pract."},{"key":"bibr6-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9"},{"key":"bibr7-08897077.2015.1010031","unstructured":"Rappaport R. Overview of the September 16, 2010 PDAC Meeting to Discuss Efficacy Supplement to NDA 21-897 for Vivitrol (naltrexone for extended-release injectable suspension) for prevention of relapse in recently-detoxified opioid dependent patients [Memorandum]. Available at: http:\/\/www.fda.gov\/downloads\/Advi-soryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/ucm225655.pdf. Published 2010. Accessed November 5, 2014."},{"key":"bibr8-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.04.018"},{"issue":"3","key":"bibr9-08897077.2015.1010031","author":"Mattick RP","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"bibr10-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1402780"},{"key":"bibr11-08897077.2015.1010031","unstructured":"Drug Addiction Treatment Act of 2000 (DATA 2000), Title XXXV, Section 3502. Available at: http:\/\/buprenorphine.samhsa.gov\/data.html."},{"key":"bibr12-08897077.2015.1010031","unstructured":"Substance Abuse and Mental Health Services Administration. An introduction to Extended-Release Injectable Naltrexone for the Treatment of People With Opioid Dependence. Advisory. 2012;11(1). Available at: https:\/\/store.samhsa.gov\/shin\/content\/SMA12-4682\/SMA12-4682.pdf"},{"key":"bibr13-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2012.03.002"},{"key":"bibr14-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006140.pub2"},{"key":"bibr15-08897077.2015.1010031","first-page":"S235","author":"Baser O","year":"2011","journal-title":"Am J Manag Care."},{"issue":"2","key":"bibr16-08897077.2015.1010031","author":"Mattick RP","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"bibr17-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001333.pub2"},{"key":"bibr18-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2011.643988"},{"key":"bibr19-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1080\/00952990802342899"},{"key":"bibr20-08897077.2015.1010031","unstructured":"National Institute for Health and Clinical Excellence. NICE Technology Guidance: Methadone and Buprenorphine for the Management of Opioid Dependence [TA114]. London: National Institute for Health and Clinical Excellence; 2007. Available at: http:\/\/www.nice.org.uk\/guidance\/TA114\/chapter\/1-Guidance. Accessed November 5, 2014."},{"key":"bibr21-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03140.x"},{"key":"bibr22-08897077.2015.1010031","unstructured":"World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization; 2009. Available at: http:\/\/www.who.int\/substance_abuse\/publications\/opioid_dependence_guidelines.pdf. Accessed November 5, 2014."},{"key":"bibr23-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.2.210"},{"key":"bibr24-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.01.005"},{"key":"bibr25-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2007.04.008"},{"key":"bibr26-08897077.2015.1010031","unstructured":"Substance Abuse and Mental Health Services Administration. Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence. Advisory. 2007;6(1). Available at: https:\/\/store.samhsa.gov\/shin\/content\/SMA07-4267\/SMA07-4267.pdf"},{"key":"bibr27-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1007\/BF02384199"},{"key":"bibr28-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2007.58.8.1041"},{"key":"bibr29-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.0480"},{"key":"bibr30-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.04.006"},{"key":"bibr31-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-010-0135-5"},{"key":"bibr32-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00169-8"},{"key":"bibr33-08897077.2015.1010031","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523010-00007"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2015.1010031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2015.1010031","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2015.1010031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:46:00Z","timestamp":1777625160000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2015.1010031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1080\/08897077.2015.1010031"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2015.1010031","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}